Ensysce Biosciences (ENSC) Interest Coverage Ratio (2020 - 2025)
Ensysce Biosciences' (ENSC) quarterly Interest Coverage Ratio came in at 587.39 in Q3 2025, down 470.16% year-over-year from 158.69 in Q3 2024, and down 6.03% quarter-over-quarter from 553.96 in Q2 2025.
Powered by 
Analysis
Ensysce Biosciences (ENSC) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Interest Coverage Ratio for 6 consecutive years, with 587.39 the latest figure, recorded in Q3 2025.
- On a quarterly basis, Interest Coverage Ratio fell 470.16% year-over-year to 587.39 in Q3 2025; TTM through Sep 2025 was 457.19, a 11671.38% decrease from a year earlier, with the FY2024 full-year figure at 5.22, up 82.78% from the prior year.
- Interest Coverage Ratio was 587.39 for Q3 2025 at Ensysce Biosciences, down from 553.96 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 158.69 in Q3 2024 and troughed at 1710.91 in Q1 2023.
- A 5-year average of 372.99 and a median of 253.24 in 2022 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio tumbled 41098.85% in 2022 and soared 144.83% in 2024, its largest moves.
- Over 5 years, Interest Coverage Ratio stood at 160.71 in 2021, then gained by 25.6% to 119.56 in 2022, then soared by 92.35% to 9.15 in 2023, then sank by 3534.11% to 332.6 in 2024, then sank by 76.6% to 587.39 in 2025.
- The last three Interest Coverage Ratio figures came in at 587.39 (Q3 2025), 553.96 (Q2 2025), and 510.25 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 10.28 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 3.65 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -21.24 |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1,199.14 |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 114.07 |
| 10 | Ensysce Biosciences | 1.18 Mn | -3.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -587.39 |
| Jun 30, 2025 | -553.96 |
| Mar 31, 2025 | -510.25 |
| Dec 31, 2024 | -332.60 |
| Sep 30, 2024 | 158.69 |
| Jun 30, 2024 | -70.94 |
| Mar 31, 2024 | -1.48 |
| Dec 31, 2023 | -9.15 |
| Sep 30, 2023 | -353.94 |
| Mar 31, 2023 | -1,710.91 |
| Dec 31, 2022 | -119.56 |
| Sep 30, 2022 | -1,268.43 |
| Jun 30, 2022 | -186.74 |
| Mar 31, 2022 | -319.74 |
| Dec 31, 2021 | -160.71 |
| Sep 30, 2021 | -684.78 |
| Jun 30, 2021 | -0.45 |
| Mar 31, 2021 | -1.51 |
| Dec 31, 2020 | -4.41 |
| Sep 30, 2020 | -1.87 |